Organ transplant nursing: a complete reference for nursing students

Organ transplantation is the definitive treatment for end-stage organ failure — and transplant nursing is one of the most demanding specialties in acute care. A transplant nurse must simultaneously manage a fragile surgical recovery, a carefully calibrated immunosuppression regimen, a dramatically elevated infection risk, and the ever-present threat of rejection. Understanding these priorities — and how they interact — is essential for the NCLEX and for any nurse working in renal, cardiac, hepatic, or hematologic settings. This reference covers the full clinical picture: transplant types, pre-transplant workup, surgical nursing, immunosuppression pharmacology, the three rejection categories, graft-versus-host disease, infection prevention, and patient education.

Transplant types and epidemiology

More than 46,000 organ transplants are performed in the United States each year, coordinated through the United Network for Organ Sharing (UNOS) and the Organ Procurement and Transplantation Network (OPTN). The most common transplants by volume:

Kidney transplant is by far the most common solid organ transplant and the one most tested on the NCLEX. Patients with ESRD on the kidney waitlist may wait years for a deceased-donor organ, or can receive a living-donor kidney from a compatible family member or altruistic donor. See the CKD and ESRD nursing reference for the underlying pathophysiology.

Hematopoietic stem cell transplantation (HSCT) — also called bone marrow transplant — differs fundamentally from solid organ transplantation. The recipient’s immune system is intentionally ablated before transplant. Graft-versus-host disease (GvHD), discussed separately below, is a complication unique to HSCT.

Pre-transplant: candidacy and workup

Transplant candidacy evaluation is multidisciplinary and exhaustive. A patient is listed only after clearing medical, surgical, psychological, and social criteria. Nursing plays a key role in coordinating pre-transplant assessments.

Medical candidacy criteria

General requirements (all organs):

• End-stage organ failure with no viable medical alternative
• Absence of active malignancy (most programs require 2–5 year cancer-free period)
• No active, untreated infection or sepsis
• Adequate functional status (patient must survive surgery and immunosuppression)
• Absence of severe comorbidity that would negate transplant benefit

Absolute contraindications: active substance use disorder (without sobriety documentation), ongoing non-adherence to medical treatment, severe irreversible multiorgan failure, metastatic cancer.

Workup components

Panel reactive antibody (PRA) deserves special attention. The PRA percentage estimates the proportion of donor HLA antigens a recipient would react against based on prior sensitization events — previous transfusions, pregnancies, or prior transplants. A PRA of 80% means the patient would react against 80% of potential donors. High PRA patients wait longer and face higher rejection risk.

Waitlist management (UNOS/OPTN)

UNOS administers the national waitlist. Allocation varies by organ:

• Kidney: points-based system incorporating wait time, HLA matching, recipient age, and dialysis time
• Liver: MELD (Model for End-Stage Liver Disease) score — higher MELD = sicker patient = prioritized. MELD uses creatinine, bilirubin, and INR. See the liver failure nursing reference for MELD context.
• Heart: UNOS Status system — Status 1 (hospitalized, mechanical support) prioritized over Status 6 (stable on oral medications)
• Lung: LAS (Lung Allocation Score) — balances urgency and expected post-transplant survival

Surgical nursing care

Kidney transplant

The kidney is placed heterotopically — in the right or left iliac fossa (pelvis), not where the native kidneys sit. The native kidneys are typically left in place unless they are causing active problems (recurrent infections, uncontrolled hypertension, polycystic disease causing mass effect). Three anastomoses are performed: renal artery to iliac artery, renal vein to iliac vein, and ureter to bladder. The ureter is typically stented initially to protect the anastomosis.

Immediate post-op nursing priorities:

• Urine output monitoring — target >30 mL/hr initially; the transplanted kidney is the primary indicator of graft function. Oliguria in the first 24 hours requires prompt evaluation.
• Fluid balance — IV fluids titrated to replace UOP in the early post-op period
• Stent management — ureteral stent is typically removed at 4–6 weeks via cystoscopy
• Graft site assessment — palpate for tenderness, firmness, change in size (graft swelling suggests rejection or obstruction)
• Creatinine trend — falling creatinine in the first 48–72 hours confirms immediate graft function

Delayed graft function (DGF): approximately 20–30% of deceased-donor kidney recipients develop DGF — the kidney produces little or no urine initially and requires temporary dialysis. Extended cold ischemia time is the primary risk factor. DGF resolves over days to weeks as tubular cells recover. Patients still need careful fluid management to avoid volume overload.

Cold ischemia time

Cold ischemia time (CIT) is the interval from when the organ is flushed with cold preservation solution to when it is reperfused in the recipient. CIT limits are organ-specific and strictly observed:

• Kidney: up to 24–36 hours (functional though DGF risk rises)
• Liver: 12–18 hours
• Heart: 4–6 hours (highly metabolically active)
• Lung: 4–6 hours

Prolonged CIT causes ischemia-reperfusion injury, increasing rejection risk and DGF. Heart and lung transplants operate under the tightest time constraints, driving the coordination urgency for those procurements.

Immunosuppression: the three pillars

All solid organ transplant recipients receive lifelong immunosuppression. The standard approach uses three drug classes simultaneously, each targeting a different step in T-cell activation. This combination achieves effective rejection prevention while keeping individual drug doses — and thus side effects — lower than any single agent could accomplish alone.

Tacrolimus nephrotoxicity — the critical NCLEX point

Tacrolimus is the backbone of most modern immunosuppression protocols, but it is directly nephrotoxic. This creates a management paradox in kidney transplant recipients: the drug preventing rejection is also slowly injuring the transplanted kidney. Tacrolimus causes afferent arteriolar vasoconstriction, reducing GFR, and with chronic use causes calcineurin inhibitor nephropathy — fibrosis that resembles chronic rejection on biopsy.

Clinical implication for nurses: rising creatinine in a stable transplant patient may represent either tacrolimus toxicity (drug level too high) or acute rejection (drug level too low). The drug level distinguishes these — which is why tacrolimus trough monitoring is a standing daily order in most transplant units. A supratherapeutic level with rising creatinine points to toxicity; a subtherapeutic level with rising creatinine points to rejection.

For broader context on drug classes in nursing practice, see the drug classifications nursing reference.

Rejection: types, mechanisms, and nursing response

Rejection is the immune system recognizing the transplanted organ as foreign and attacking it. There are three distinct categories, each with different timing, mechanism, clinical presentation, and treatment. These distinctions are high-yield NCLEX content.

Nursing assessment for rejection

Any of the following in a post-transplant patient requires immediate reporting to the transplant team:

• Kidney: rising creatinine (>20–25% increase from baseline), decreased urine output, fever, graft site tenderness or swelling, hypertension
• Liver: rising bilirubin, elevated AST/ALT/alkaline phosphatase, jaundice, right upper quadrant pain, fever. See liver failure nursing for LFT interpretation.
• Heart: decreased cardiac output, new dyspnea, fatigue, edema, arrhythmias, hypertension
• Lung: decreased SpO2, declining FEV1, new infiltrates on imaging, dyspnea

Biopsy remains the gold standard for rejection confirmation. Nurses prepare patients for graft biopsy, monitor for post-procedure bleeding, and ensure accurate drug level specimens are drawn at trough (just before the next scheduled dose).

Graft-versus-host disease (GvHD) — HSCT only

GvHD is a complication exclusive to hematopoietic stem cell transplantation (HSCT) — it does not occur in solid organ transplantation. This distinction is a common NCLEX trap. In solid organ transplants, the recipient’s immune system attacks the donor organ (host-versus-graft). In HSCT, the immunologic relationship is reversed: the donor’s transplanted immune cells (graft) recognize the recipient’s body (host) as foreign and attack it.

GvHD occurs because the donor marrow contains T-lymphocytes that survived the conditioning regimen and recognize host HLA antigens as foreign. The severity of HLA mismatch is the primary risk factor.

Acute GvHD

Onset: within 100 days of HSCT (most within the first few weeks)

Target organs and clinical features:

Overall grading: Grade I (mild skin only) through Grade IV (severe involvement of skin, GI, and liver — high mortality).

Treatment: High-dose corticosteroids (methylprednisolone 1–2 mg/kg/day) are first-line. Steroid-refractory GvHD carries >50% mortality and is treated with ruxolitinib (JAK inhibitor — FDA-approved 2019), extracorporeal photopheresis, or other agents.

Chronic GvHD

Onset: after day 100 (though modern classification uses clinical features more than strict timing)

Chronic GvHD resembles autoimmune disease. It can affect virtually any organ system: dry eyes (keratoconjunctivitis sicca), dry mouth (sicca syndrome), skin fibrosis (scleroderma-like changes), fascia involvement limiting range of motion, obstructive lung disease (bronchiolitis obliterans), liver cholestasis, GI strictures, and cytopenias.

Nursing priorities in GvHD:

• Monitor fluid balance closely (diarrhea causes severe dehydration and electrolyte disturbances)
• Meticulous skin care — avoid trauma to fragile skin; barrier dressings for blistered areas
• Oral care — mouth sores and mucositis are universal in acute GvHD; dilute rinses, soft diet, adequate analgesia
• Nutritional support — TPN often required in severe GI GvHD
• Monitor for secondary infection — GvHD treatment requires intensifying an already maximal immunosuppression regimen

Infection prevention: the highest-risk period

Infection is the leading cause of death in transplant recipients during the first year. The transplanted organ replaces one lethal risk (organ failure) with another (fatal infection from immunosuppression). The infection risk profile changes over time:

• 0–30 days post-transplant: surgical and nosocomial infections dominate — wound infections, urinary tract infections (common post-kidney transplant with Foley catheters and ureteral stents), Clostridioides difficile, and donor-derived infections
• 1–6 months: opportunistic pathogens emerge as immunosuppression reaches therapeutic levels — CMV (cytomegalovirus), PCP (Pneumocystis jirovecii pneumonia), fungal infections (Candida, Aspergillus), BK polyomavirus (renal transplant — causes BK nephropathy)
• >6 months: community-acquired infections if immunosuppression stable; late opportunistic infections if rejection episodes have required additional immunosuppression

Standard prophylaxis protocols

Nursing infection prevention priorities

Transplant recipients require enhanced infection precautions that go beyond standard universal precautions. The immune system that protects a healthy patient cannot protect a transplant recipient — so the environment must do that work instead.

• Hand hygiene is the single most effective intervention. All staff, visitors, and the patient must use rigorous hand hygiene technique. See the infection control and isolation precautions reference for standard protocols.
• Protective environment rooms (positive pressure, HEPA filtration): required for HSCT patients and often used for lung transplant recipients
• Neutropenic diet (HSCT, high-dose immunosuppression): avoid raw fruits and vegetables, well water, fresh-squeezed juices
• Line care: central lines, Foley catheters, and surgical drains are infection conduits — remove as soon as clinically possible
• Vaccination review: live vaccines are contraindicated post-transplant (MMR, varicella, live flu, yellow fever). Inactivated vaccines (influenza, pneumococcal, hepatitis B) are encouraged but may have reduced efficacy.
• Sick visitor restriction: visitors with any respiratory symptoms, fever, or recent illness should not visit

When to escalate: Any fever ≥38°C (100.4°F) in a transplant recipient is a medical emergency until proven otherwise. The normal inflammatory response is suppressed — these patients may have life-threatening sepsis with only mild symptoms. Report immediately and anticipate blood cultures, chest X-ray, urinalysis, and empiric antibiotics.

Organ-specific post-transplant nursing care

Post-kidney transplant

The post-kidney transplant patient requires intensive monitoring of renal function, fluid balance, and immunosuppression levels.

Key nursing assessments:

• Urine output hourly for the first 24–48 hours — target >30 mL/hr; oliguria (<0.5 mL/kg/hr) requires immediate evaluation
• Daily weights — fluid retention indicates possible rejection or calcineurin inhibitor-related hypertension
• Creatinine and BMP daily (or more frequently in the early post-op period) — creatinine should fall predictably in a functioning graft
• Blood pressure — hypertension is nearly universal post-kidney transplant (calcineurin inhibitors, steroids, residual disease) and requires treatment to protect the graft
• Wound and graft site — assess for hematoma, seroma, lymphocele (lymphatic disruption at the graft site — common, usually self-limiting)
• Foley catheter — maintain patency; bladder spasms are common in the early post-op period with the ureteral stent in place

The AKI nursing reference provides a useful framework for interpreting urine output changes and rising creatinine in the post-transplant setting.

Post-liver transplant

The liver graft must perform multiple simultaneous metabolic functions from day one. Primary non-function (PNF) — the graft never works — is the most feared early complication and requires emergency retransplantation.

Key nursing assessments:

• LFTs (AST, ALT, bilirubin, alkaline phosphatase, GGT) — trending downward signals graft function; rising values suggest rejection, ischemia, or biliary complication
• INR/PT — a functioning liver graft will begin producing clotting factors; improving coagulopathy is a good prognostic sign
• Bile output via T-tube (if placed) — bilious output confirms hepatocyte function; pale or absent bile suggests graft dysfunction
• Biliary complications — bile leak and biliary strictures are common; monitor for worsening jaundice, fever, right upper quadrant pain, rising bilirubin
• Hepatic artery thrombosis (HAT) — most feared early vascular complication; sudden severe LFT elevation, graft tenderness; requires urgent Doppler ultrasound

Patients with underlying hepatic encephalopathy may have neuropsychiatric symptoms in the post-op period. The hepatic encephalopathy nursing reference covers ammonia management and neurological assessment.

Post-heart transplant

The denervated transplanted heart has no autonomic innervation — it cannot respond to vagal maneuvers, and atropine has no effect on heart rate. Heart rate is determined by the intrinsic rate of the SA node and circulating catecholamines. This affects clinical management significantly.

Key nursing assessments:

• Cardiac output and hemodynamic stability — expect a baseline resting heart rate of 90–110 bpm (normal for a denervated heart)
• Atrial arrhythmias — two P waves may be visible on EKG in the early post-op period (recipient remnant atrium + donor SA node)
• Acute rejection surveillance via endomyocardial biopsy — required at regular intervals for the first 1–2 years; rejection is often clinically silent in the heart until graft function deteriorates
• Transplant coronary artery disease (TCAD) — accelerated vasculopathy due to chronic immune injury; routine annual angiography or IVUS screening
• Signs of heart failure — the denervated heart cannot compensate as quickly as a normal heart; volume status must be carefully managed

Patient education priorities

Transplant patient education begins before listing and continues for life. Non-adherence to immunosuppression is the leading preventable cause of late graft loss. The transplant nurse is responsible for ensuring the patient understands the following:

Immunosuppression adherence (highest priority)

• Lifelong medication — missing doses even briefly can precipitate acute rejection
• Take tacrolimus at the same time every day — consistent timing is essential for stable trough levels
• Never adjust or stop immunosuppression without contacting the transplant team
• Drug interactions: St. John’s wort, azole antifungals, grapefruit juice all alter tacrolimus/cyclosporine levels significantly

Infection recognition and response

• Report any fever ≥38°C (100.4°F) immediately to the transplant team — do not wait
• Avoid raw or undercooked foods; food safety is critical with suppressed immunity
• Avoid anyone with known illness or recent live vaccine exposure
• Annual inactivated influenza vaccine; pneumococcal vaccination per schedule

Rejection warning signs to report immediately

• Decreased urine output, weight gain, leg swelling, graft site tenderness (kidney)
• Jaundice, abdominal pain, dark urine (liver)
• Fatigue, new dyspnea, reduced exercise tolerance (heart)
• Fever in any transplant recipient

Medication side effects to monitor and report

• Tremor, headache (tacrolimus neurotoxicity)
• Severe GI symptoms — nausea, diarrhea, vomiting affecting medication tolerance (MMF)
• Glucose monitoring — corticosteroids cause hyperglycemia; post-transplant diabetes mellitus (PTDM) develops in 15–30% of recipients

Lifestyle and follow-up

• Sun protection: squamous cell carcinoma and other skin cancers are significantly more common under long-term immunosuppression
• Annual dermatology evaluation for all transplant recipients
• Regular transplant clinic follow-up — initially weekly then monthly, eventually quarterly; lab draws every visit
• Healthy lifestyle: blood pressure control, lipid management, weight management all reduce chronic rejection risk

NCLEX tips: organ transplant nursing

The NCLEX tests transplant nursing across multiple categories — pharmacology, med-surg, prioritization, and patient education. These are the high-yield concepts most likely to appear:

• Rejection timing is definitive. Hyperacute = minutes to 24 hours (irreversible). Acute = days to 1 year, peak in first 3 months (treat with steroids). Chronic = months to years (no effective treatment). Know these timing windows.
• Tacrolimus is nephrotoxic. Rising creatinine in a stable kidney transplant patient may be tacrolimus toxicity. Check the trough level — supratherapeutic level + rising creatinine = toxicity (reduce dose). Subtherapeutic level + rising creatinine = possible rejection (increase immunosuppression).
• GvHD occurs only in HSCT, not solid organ transplant. The direction reverses: in HSCT, the graft attacks the host. Solid organ recipients never develop GvHD.
• Post-kidney transplant UOP target is >30 mL/hr. Oliguria in the first 24 hours is a priority finding requiring immediate reporting.
• Hyperacute rejection is irreversible — remove the organ. No treatment restores a hyperactively rejected graft. The graft must be removed.
• CMV prophylaxis = valganciclovir. Standard in CMV-mismatched transplant pairs (donor+/recipient–). Know the drug name.
• PCP prophylaxis = trimethoprim-sulfamethoxazole (TMP-SMX). Started post-transplant routinely. TMP-SMX also covers Toxoplasma.
• Azole antifungals increase tacrolimus levels. Fluconazole inhibits CYP3A4 — co-administration raises tacrolimus to potentially toxic levels. Always check drug interactions.
• Live vaccines are contraindicated post-transplant. MMR, varicella, live flu — all contraindicated. Inactivated vaccines are recommended.
• Fever in a transplant patient = emergency. The immunosuppressed patient may have life-threatening sepsis with only low-grade fever. Treat as urgent, obtain cultures, anticipate empiric antibiotics immediately.
• The denervated heart does not respond to atropine. After heart transplant, atropine has no effect on bradycardia — the vagus nerve was severed. Use isoproterenol or pacing instead.
• Grapefruit juice is contraindicated with tacrolimus and cyclosporine. It inhibits CYP3A4 intestinal metabolism, raising drug levels unpredictably.
• MELD score determines liver transplant priority. Higher MELD = sicker patient = listed higher. Know the three components: creatinine, bilirubin, INR.

Related articles

• CKD and ESRD nursing reference — the underlying disease driving most kidney transplants
• AKI nursing reference — interpreting post-transplant creatinine changes
• Infection control and isolation precautions — standard precautions framework for transplant settings
• Drug classifications nursing reference — immunosuppressive drug class overview
• Heart failure nursing reference — hemodynamic management relevant to post-cardiac transplant care
• Liver failure nursing — MELD score and LFT interpretation
• Hepatic encephalopathy nursing reference — post-liver transplant neurological monitoring
• Sepsis nursing reference — fever management in the immunosuppressed patient
• Perioperative nursing reference — surgical nursing framework for transplant procedures